Advertisement
Clinical Therapeutics
Advanced searchSave search
Review Article| Volume 17, ISSUE 6, P1005-1030, November 1995

Download started.

Ok

Angiotensin II receptor antagonism: Losartan—sites and mechanisms of action

  • David J. Triggle
    Correspondence
    Address correspondence to: David J. Triggle, PhD, School of Pharmacy, State University of New York at Buffalo, C-126 Cooke Hall, Buffalo, NY 14260-1200.
    Affiliations
    School of Pharmacy, State University of New York at Buffalo, Buffalo, New York U.S.A.
    Search for articles by this author
DOI:https://doi.org/10.1016/0149-2918(95)80080-8
Angiotensin II receptor antagonism: Losartan—sites and mechanisms of action
Previous ArticleEditorial comment
Next ArticleEditorial comment
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      This review surveys the basic pharmacology of angiotensin II receptors and their antagonism; reviews the existing clinical experience with losartan, the first approved nonpeptide angiotensin II antagonist; suggests other possible clinical areas for angiotensin II receptor antagonism; and compares angiotensin-converting enzyme inhibition with angiotensin receptor antagonism.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health, Bethesda, Md1993 (Publication No 93-1088)
        • Tobian L
        • Brunner HR
        • Cohn JN
        • et al.
        Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from JNC V Consensus Guidelines.
        Am J Hypertens. 1994; 7: 859-872
        • Timmermans PBMWM
        • Wong PC
        • Chiu AT
        • et al.
        Angiotensin receptors and angiotensin II receptor antagonists.
        Pharmacol Rev. 1993; 45: 205-251
        • Campbell DJ
        Circulating and tissue angiotensin systems.
        J Clin Invest. 1987; 79: 1-6
        • Dzau VJ
        Circulating versus local renin-angiotensin system in cardiovascular homeostasis.
        Circulation. 1988; 77 (Suppl I): I-4-I-13
        • Brunner HR
        • Gavras H
        • Laragh JR
        • Keenan R
        Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood pressure.
        Lancet. 1973; 2: 1045-1048
        • Pals DT
        • Masucci FD
        • Denning Jr, GS
        • et al.
        Role of the pressor action of angiotensin II in experimental hypertension.
        Circ Res. 1971; 29: 673-681
        • Case DB
        • Wallace JM
        • Keim HJ
        • et al.
        Estimating renin participation in hypertension: Superiority of converting enzyme inhibitor over saralasin.
        Am J Med. 1976; 61: 790-796
        • Carini DJ
        • Duncia JV
        • Aldrich PE
        • et al.
        Nonpeptide angiotensin II receptor antagonists: The discovery of a series of N-(biphenylmethyl) imidazoles as potent, orally-active antihypertensives.
        J Med Chem. 1991; 34: 2525-2547
        • Duncia JV
        • Chiu AT
        • Carini DJ
        • et al.
        The discovery of potent nonpeptide angiotensin II receptor antagonists: A new class of potent antihypertensives.
        J Med Chem. 1990; 33: 1312-1329
        • Siegl PKS
        Discovery of losartan, the first specific nonpeptide angiotensin II receptor antagonist.
        J Hypertens Suppl. 1993; 11: S19-S22
        • Smith RD
        • Chiu AT
        • Wong PC
        • et al.
        Pharmacology of nonpeptide angiotensin II receptor antagonists.
        Annu Rev Pharmacol Toxicol. 1992; 32: 135-165
        • Wexler RR
        • Carini DJ
        • Duncia JV
        • et al.
        Rationale for the chemical development of angiotensin II receptor antagonists.
        Am J Hypertens. 1992; 5 (12 Pt 2): 209S-220S
        • Furukawa Y
        • Kishimoto S
        • Nishikawa K
        (Issued to)Hypotensive imidazole derivatives. Takeda Chemical Industries Ltd, Osaka, Japan1982 (US Patent 4,340,598)
        • Furukawa Y
        • Kishimoto S
        • Nishikawa K
        (Issued to)Hypotensive imidazole-5-acetic acid derivatives. Takeda Chemical Industries Ltd, Osaka, Japan1982 (US Patent 4,355,040)
        • Chiu AT
        • Carini DJ
        • Johnson AL
        • et al.
        Non-peptide angiotensin II receptor antagonists. II. Pharmacology of S-8308.
        Eur J Pharmacol. 1988; 157: 13-21
        • Wong PC
        • Chiu AT
        • Price WA
        • et al.
        Non-peptide angiotensin II receptor antagonists. I. Pharmacological characterization of 2-n-butyl-4-chloro-1-(2-chlorobenzyl) imidazole-5-acetic acid, sodium salt (S-8307).
        J Pharmacol Exp Ther. 1988; 247: 1-7
        • Duncia JV
        • Carini DJ
        • Chiu AT
        • et al.
        The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist.
        Med Res Rev. 1992; 12: 149-191
        • Chiu AT
        • Duncia JV
        • McCall DE
        • et al.
        Nonpeptide angiotensin II receptor antagonists. III. Structure-function studies.
        J Pharmacol Exp Ther. 1989; 250: 867-874
        • Timmermans PBMWM
        • Carini DJ
        • Chiu AT
        • et al.
        Nonpeptide angiotensin II receptor antagonists: A novel class of anti-hypertensive agents.
        Blood Vessels. 1990; 27: 295-300
        • Wong PC
        • Price WA
        • Chiu AT
        • et al.
        Nonpeptide angiotensin II receptor antagonists. IV. EXP 6155 and EXP 6803.
        Hypertension. 1989; 13: 489-497
        • Perlman S
        • Schambye HT
        • Rivero RA
        • et al.
        Nonpeptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor.
        J Biol Chem. 1995; 270: 1493-1496
        • Chiu AT
        • McCall DE
        • Price WA
        • et al.
        Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent.
        J Pharmacol Exp Ther. 1990; 252: 711-718
        • Chiu AT
        • McCall DE
        • Price WA
        In vitro pharmacology of DuP 753.
        Am J Hypertens. 1991; 4 (4 Pt 2): 282S-287S
        • Timmermans PBMWM
        • Wong PC
        • Chiu AT
        • Herblin WF
        Nonpeptide angiotensin II receptor antagonists.
        Trends Pharmacol Sci. 1991; 12: 55-62
        • Wong PC
        • Hart SD
        • Zaspel A
        • et al.
        Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2).
        J Pharmacol Exp Ther. 1990; 255: 584-592
        • Wong PC
        • Tam SW
        • Herblin WF
        • Timmermans PBMWM
        Further studies on the selectivity of DuP 753, a nonpeptide angiotensin II receptor antagonist.
        Eur J Pharmacol. 1991; 196: 201-203
        • Barnes JC
        • Brown JD
        • Hancock AB
        • Michel RD
        Angiotensin II-induced contractions of the isolated pupa of rat uterus are mediated through the AT1 receptor.
        Br J Pharmacol. 1991; 104 (Abstract): 43P
        • Rhaleb NE
        • Rouisi N
        • Nantel F
        • et al.
        DuP 753 is a specific antagonist for the angiotensin receptor.
        Hypertension. 1991; 17: 480-484
        • Chang RS
        • Lotti VJ
        Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands.
        Mol Pharmacol. 1990; 37: 347-351
        • Koepke JP
        • Bovis PR
        • McMahon EG
        • et al.
        Central and peripheral actions of a nonpeptide angiotensin II receptor antagonist.
        Hypertension. 1990; 15: 841-847
        • Wong PC
        • Price Jr, WA
        • Chiu AT
        • et al.
        Nonpeptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP 753.
        Hypertension. 1990; 15: 823-834
        • Wong PC
        • Price WA
        • Chiu AT
        • et al.
        Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.
        J Pharmacol Exp Ther. 1990; 252: 719-725
        • Wong PC
        • Price WA
        • Chiu ET
        • et al.
        In vivo pharmacology of Du P753.
        Am J Hypertens. 1991; 4 (4 Pt 2): 288S-298S
        • Beauchamp HT
        • Chang RSL
        • Siegl PKS
        • Gibson RE
        In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: Relationship to in vitro affinities and in vivo pharmacologic potency.
        J Pharmacol Exp Ther. 1995; 272: 612-618
        • Wood JM
        • Mah SC
        • Schnell C
        Comparison of the acute hypotensive effects of renin inhibition, converting enzyme inhibition, and angiotensin II antagonism in rats.
        J Cardiovasc Pharmacol. 1990; 16 (Suppl 4): S60-S64
        • Ignasiak DP
        • Peterson JT
        • Keiser JA
        Cardiovascular effects of DuP 753 in Na-depleted anesthesized dogs.
        FASEB J. 1991; 5 (Abstract): A1413
        • MacFadyen RJ
        • Tree M
        • Lever AF
        • Reid JL
        Hemodynamic and neurohumoral responses to infusion of an angiotensin receptor antagonist in the conscious salt-depleted beagle.
        FASEB J. 1991; 5 (Abstract): A1767
        • Wong PC
        • Price WA
        • Chiu AT
        • et al.
        Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent.
        J Pharmacol Exp Ther. 1990; 252: 726-732
        • Wong PC
        • Price WA
        • Chiu AT
        • et al.
        Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists. X.
        Hypertension. 1990; 15: 459-468
        • Stearns RA
        • Miller RR
        • Doss GA
        • et al.
        The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey and human liver slices.
        Drug Metab Dispos. 1992; 20: 281-287
        • Christ D
        • Kilkson T
        • Wong N
        • Lam G
        Formation and disposition of EXP 3174, a pharmacologically active metabolite of the novel angiotensin II receptor antagonist DuP 753.
        Third North American Meeting of the International Society for the Study of Xenobiotics 1990. 21251990; (Presented at the) (New York, New York. Abstract no. 34)
        • Wong PC
        • Price WA
        • Chiu AT
        • et al.
        Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP 31374: An active metabolite of DuP 753, an orally active antihypertensive agent.
        J Pharmacol Exp Ther. 1990; 255: 211-217
        • Whitebread S
        • Mele M
        • Kamber B
        • de Gasparo M
        Preliminary biochemical characterization of two angiontensin II receptor subtypes.
        Biochem Biophys Res Commun. 1989; 163: 284-291
        • Bumpus FM
        • Catt KJ
        • Chiu AT
        • et al.
        Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research.
        Hypertension. 1991; 17: 720-721
        • Dudley DJ
        • Panek RL
        • Major TC
        • et al.
        Subclasses of angiotensin II binding sites and their functional significance.
        Mol Pharmacol. 1990; 38: 370-377
        • Dzau VJ
        • Mikayama M
        • Pratt RE
        Molecular biology of angiotensin receptors: Target for drug research?.
        J Hypertens Suppl. 1994; 12: S1-S5
        • Chang LL
        • Ashton WT
        • Flanagan KL
        • et al.
        Potent triazolinone-based angiotensin II receptor antagonists with equivalent affinity for both the AT1 and AT2 subtypes.
        Bioorg Med Chem Lett. 1994; 4: 2787-2792
        • de Laszlo SE
        • Quagliato CS
        • Greenlee WJ
        • et al.
        A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor.
        J Med Chem. 1993; 36: 3207-3210
        • Kambayashi Y
        • Bardhan S
        • Takahashi K
        • et al.
        Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition.
        J Biol Chem. 1993; 268: 24,543-24,546
        • Mukoyama M
        • Nakajima M
        • Horiuchi M
        • et al.
        Expression cloning of type 2 angiotensin receptor reveals a unique class of seven-transmembrane receptors.
        J Biol Chem. 1993; 268: 24,539-24,542
        • Murphy TJ
        • Alexander RW
        • Griendling KK
        • et al.
        Isolation of a cDNA encoding the vascular type-I angiotensin II receptor.
        Nature. 1991; 351: 233-236
        • Nakajima M
        • Mukoyama M
        • Pratt RE
        • et al.
        Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor.
        Biochem Biophys Res Commun. 1993; 197: 393-399
        • Sasaki K
        • Yamano Y
        • Bardhan S
        • et al.
        Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor.
        Nature. 1991; 351: 230-233
        • Dzau VJ
        • Sasamura H
        • Lein L
        Heterogeneity of angiotensin synthetic pathways and receptor subtypes: Physiological and pharmacological implications.
        J Hypertens Suppl. 1993; 11: S13-S18
        • Sandberg K
        • Ji H
        • Clark AJ
        • et al.
        Cloning and expression of a novel angiotensin II receptor subtype.
        J Biol Chem. 1992; 267: 9455-9458
        • Sasamura H
        • Hein L
        • Krieger J
        • et al.
        Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome.
        Biochem Biophys Res Commun. 1992; 185: 253-259
        • Steckelings VM
        • Bottari SP
        • Unger T
        Angiotensin receptor subtypes in the brain.
        Trends Pharmacol Sci. 1992; 13: 365-368
        • Bauer PH
        • Chiu AT
        • Garrison JC
        DuP 753 can antagonize the effects of angiotensin II in rat liver.
        Mol Pharmacol. 1991; 39: 579-585
        • Pfeilschifter J
        Angiotensin II B-type receptor mediates phosphoinositide hydrolysis in mesangial cells.
        Eur J Pharmacol. 1990; 184: 201-202
        • Bottari SP
        • King IN
        • Reichlin S
        • et al.
        The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase.
        Biochem Biophys Res Commun. 1992; 183: 206-211
        • Sweet CS
        • Nelson EB
        How well have animal studies with losartan predicted responses in humans?.
        J Hypertens Suppl. 1993; 11: S63-S67
        • Christen Y
        • Waever B
        • Nussberger J
        • et al.
        Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.
        Circulation. 1991; 83: 1333-1342
        • Munafo A
        • Christen Y
        • Nussberger J
        • et al.
        Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist.
        Clin Pharmacol Ther. 1992; 51: 513-521
        • Weber MA
        Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report.
        Am J Hypertens. 1992; 5 (Supp): 247S-251S
        • Foote EF
        • Halstenson CE
        New therapeutic agents in the management of hypertension: Angiotensin II receptor antagonists and renin inhibitors.
        Ann Pharmacother. 1993; 27: 1495-1505
        • Goldberg MR
        • Tanaka W
        • Barclowsky A
        • et al.
        Effects of losartan and blood pressure, plasma renin activity, and angiotensin II in volunteers.
        Hypertension. 1993; 21: 704-713
        • Ohtawa M
        • Takayama F
        • Saitoh K
        • et al.
        Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans.
        Br J Clin Pharmacol. 1993; 35: 290-297
        • Lo MW
        • Shahinfar S
        • Furtek CI
        • et al.
        Pharmacokinetics of losartan (MK-954 or DuP-753) in patients with renal insufficiency.
        Clin Pharmacol Ther. 1993; 53 (Abstract PI-100): 160
        • Brunner HR
        • Nussberger J
        • Waeber B
        Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system.
        J Hypertens Suppl. 1993; 11: S53-S58
        • Goldberg MR
        • Bradstreet TE
        • McWilliams EJ
        • et al.
        Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.
        Hypertension. 1995; 25: 37-46
        • Nelson E
        • Merrill D
        • Sweet C
        • et al.
        Efficacy and safety of oral MK 954 (DuP 753), an angiotensin receptor antagonist in essential hypertension.
        J Hypertens. 1991; 9 (Abstract): S468-S469
        • Nelson E
        • Arcuri K
        • Ikeda L
        • et al.
        Efficacy and safety of losartan in patients with essential hypertension.
        Am J Hypertens. 1992; 5 (Abstract): 19A
        • Eberhardt RT
        • Kevak RM
        • Kang PM
        • Frishman WH
        Angiotensin II receptor blockade: An innovative approach to cardiovascular pharmacotherapy.
        J Clin Pharmacol. 1993; 33: 1023-1038
        • Goldberg AJ
        • Dunlay MC
        • Sweet CS
        Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER and angiotensin converting enzyme inhibitors for the treatment of systemic hypertension.
        Am J Cardiol. 1995; 75: 793-795
        • Crozier I
        • Ikram H
        • Awan N
        • et al.
        • Losartan Hemodynamic Study Group
        Losartan in heart failure. Hemodynamic effects and tolerability.
        Circulation. 1995; 91: 691-697
        • Christen Y
        • Waeber B
        • Nussberger J
        • et al.
        Dose-response relationships following oral administration of DuP 753 to normal humans.
        Am J Hypertens. 1991; 4 (Suppl): S350-S353
        • Nakashima M
        • Uematsu T
        • Kosuge K
        • Kanamara M
        Pilot study of the uricosuric effect of DuP 753, a new angiotensin II receptor antagonist, in healthy subjects.
        Eur J Clin Pharmacol. 1992; 42: 333-335
        • Steinberg MA
        • Wiest SA
        • Palkowitz AD
        Nonpeptide angiotensin II receptor antagonists.
        Cardiovasc Drug Rev. 1993; 11: 312-358
        • Levy D
        • Garrison RJ
        • Savage DD
        • et al.
        Left ventricular mass and incidence of coronary heart disease in an elderly cohort: The Framingham Heart Study.
        Ann Intern Med. 1989; 110: 101-107
        • Baker KM
        • Booz GW
        • Dostal DE
        Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system.
        Annu Rev Physiol. 1992; 54: 227-241
        • Dahlöf B
        • Pennert K
        • Hansson L
        Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies.
        Am J Hypertens. 1992; 5: 95-110
        • Dahlöf B
        The importance of the renin-angiotensin system in reversal of left ventricular hypertrophy.
        J Hypertens Suppl. 1993; 11: S29-S35
        • Julius S
        • Li Y
        • Brant D
        • et al.
        Quinapril, an angiotensin converting enzyme inhibitor, prevents cardiac hypertrophy during episodic hypertension.
        Hypertension. 1991; 17: 1161-1166
        • Raya TE
        • Fonken SJ
        • Lee RW
        • et al.
        Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibitor in rat model of heart failure.
        Am J Hypertens. 1991; 4 (4 Pt 2): 334S-339S
        • Yamazaki T
        • Shiojima I
        • Komuro I
        • et al.
        Involvement of the renin-angiotensin system in the development of left ventricular hypertrophy and dysfunction.
        J Hypertens Suppl. 1994; 12: S23-S27
        • Captopril Multicenter Research Group
        A placebo-controlled trial of captopril in refractory chronic congestive heart failure.
        J Am Coll Cardiol. 1983; 2: 755-763
        • The CONSENSUS Trial Study Group
        Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
        NEJM. 1987; 316: 1429-1435
        • DiBianco R
        The changing syndrome of heart failure: An annotated review as we approach the 21st century.
        J Hypertens Suppl. 1994; 12: S73-S87
        • The SOLVD Investigators
        Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
        NEJM. 1991; 325: 293-302
        • Ambrosioni E
        • Borghi C
        • Magnani B
        • Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators
        The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction.
        NEJM. 1995; 332: 80-85
        • Pfeffer MA
        ACE inhibition in acute myocardial infarction.
        NEJM. 1995; 332: 118-120
        • Fitzpatrick MA
        • Rademaker MT
        • Charles CJ
        • et al.
        Angiotensin II receptor antagonism in ovine heart failure: Acute hemodynamic, hormonal and renal effects.
        Am J Physiol. 1992; 263: H250-H256
        • Gottlieb SS
        • Dickstein KD
        • Fleck E
        • et al.
        Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure.
        Circulation. 1993; 88: 1602-1609
        • Anderson S
        • Rennke HG
        • Brenner BM
        Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.
        J Clin Invest. 1986; 77: 1993-2000
        • Scholey JW
        • Miller PL
        • Rennke HG
        • Meyer TW
        Effect of converting enzyme inhibitor on the course of adriamycin-induced nephropathy.
        Kidney Int. 1989; 36: 816-822
        • Bochicchio T
        • Sandoval G
        • Ron O
        • et al.
        Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensive.
        Kidney Int. 1990; 38: 873-879
        • Brunner HR
        ACE inhibitors in renal disease.
        Kidney Int. 1992; 42: 463-479
        • Lewis EJ
        • Hunsicker LG
        • Bain RP
        • Rhode RD
        • Collaborative Study Group
        The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy.
        NEJM. 1993; 329: 1456-1462
        • ter Wee PM
        • DeMicheli AG
        • Epstein M
        Effects of calcium antagonists on renal hemodynamics and progression of non-diabetic chronic renal disease.
        Arch Intern Med. 1994; 154: 1185-1202
        • Loutzenhiser R
        • Epstein M
        • Hayashi K
        Characterization of the renal microvascular effects of the angiotensin II antagonist DuP 753L: Studies in isolated perfused hydronephrotic kidneys.
        Am J Hypertens. 1991; 4 (4 Pt 2): 309S-314S
        • Eberhardt R
        • Nowack R
        Detrimental and beneficial effects of converting enzyme inhibitors in the kidney.
        J Cardiovasc Pharmacol. 1990; 16 (Suppl 4): S70-S75
        • Burnier M
        • Rutschmann B
        • Nussberger J
        • et al.
        Salt-dependent renal effects of an angiotensin II receptor antagonist in healthy subjects.
        Hypertension. 1993; 22: 339-347
        • Jover B
        • Mimran A
        Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: Effects on renal function.
        J Hypertens Suppl. 1994; 12: S3-S9
        • Keiser JA
        • Bjork FA
        • Hodges JC
        • Taylor Jr, DG
        Renal hemodynamic and excretory responses to PD 123319 and losartan, nonpeptide AT1 and AT2 subtype-specific angiotensin II ligands.
        J Pharmacol Exp Ther. 1992; 262: 1154-1158
        • Xie MH
        • Liu FY
        • Wong PC
        • et al.
        Proximal nephron and renal effects of DuP 753, a nonpeptide angiotensin II receptor antagonist.
        Kidney Int. 1990; 38: 473-479
        • Kon V
        • Fogo A
        • Ichikawa I
        Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition.
        Kidney Int. 1993; 44: 545-550
        • Camargo JF
        • von Lutterotti N
        • Pecker MS
        • et al.
        DuP 753 increases survival in spontaneously hypertensive stroke-prone rats fed a high sodium diet.
        Am J Hypertens. 1991; 4 (4 Pt 2): 341S-345S
        • von Lutterotti N
        • Camarago JF
        • Mueller FB
        • et al.
        Angiotensin II receptor antagonist markedly reduces mortality in salt-loaded Dahl S rats.
        Am J Hypertens. 1991; 4 (4 Pt 2): 346S-349S
        • Gansevoort RT
        • de Zeeuw D
        • de Jong PE
        Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin systems?.
        Kidney Int. 1994; 45: 861-867
        • Laragh JH
        • Baer L
        • Brunner HR
        • et al.
        Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease.
        Am J Med. 1992; 52: 633-652
        • Laragh JH
        New angiotensin converting enzyme inhibitors. Their role in the management of hypertension.
        Am J Hypertens. 1990; 3 (Suppl): 257S-265S
        • Alderman M
        • Madhavan S
        • Ooi WL
        • et al.
        High renin/sodium phenotype predicts myocardial infraction (MI): Renin hypothesis confirmed.
        Circulation. 1989; 80 (Abstract): II-101
        • Fleetwood G
        • Butinet S
        • Meier M
        • Wood JM
        Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart.
        J Cardiovasc Pharmacol. 1991; 17: 351-356
        • Pfeffer MA
        • Braunwald ME
        • Moyer LA
        • et al.
        Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction and myocardial infarction. Results of the survival and ventricular enlargement trial.
        NEJM. 1992; 327: 669-677
        • Gibbons JH
        • Dzau VJ
        The emerging concept of vascular remodelling.
        NEJM. 1995; 330: 1431-1437
        • Powell JS
        • Clozel J-P
        • Muller RKM
        • et al.
        Inhibition of angiotensin-converting enzyme prevents myointimal proliferation after vascular injury.
        Science. 1989; 245: 186-188
        • Kauffman RF
        • Bean JS
        • Zimmerman KM
        • et al.
        Losartan, a nonpeptide-angiotensin II (ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries.
        Life Sci. 1991; 49: PL223-PL226
        • Aldiger JC
        • Huang H
        • Dalmay F
        • et al.
        Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans.
        J Cardiovasc Pharmacol. 1993; 21: 289-295
        • Abdelrahman AM
        • Burrell LM
        • Johnston CI
        Blockage of the renin-angiotensin system at different sites: Effect on renin, angiotensin and aldosterone.
        J Hypertens Suppl. 1993; 11: S23-S26
        • Laragh JH
        Renin system blockade as a therapeutic strategy: Past, present and future.
        Am J Hypertens. 1991; 4: 273S-274S
        • Karlberg BE
        Cough and inhibition of the renin-angiotensin system.
        J Hypertens Suppl. 1993; 11: S49-S52
        • Lacourciere Y
        • Lefebvre J
        • Nakhle G
        • et al.
        Association between cough and angiotensin converting enzyme inhibition versus angiotensin II antagonists: The design of a prospective controlled study.
        J Hypertens. 1994; 12 (Suppl 2): S49-S53
        • Lacourciere Y
        • Brunner H
        • Irwin R
        • et al.
        Effect of modulators of the renin-angiotensin-aldosterone system on cough.
        J Hypertens. 1994; 12: 1387-1393
        • Nelson DE
        • Moyse DM
        • O'Neil JM
        • et al.
        Renin inhibitor, Abbott-72517, does not induce characteristic angiotensin converting enzyme inhibitor cough.
        Circulation. 1993; 88 (Abstract 1934): I-360
        • Carretero OA
        • Miyazaki S
        • Scicli AG
        Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor, captopril.
        Hypertension. 1981; 3: 18-22
        • Anderson S
        • Jung FF
        • Ingelfinger JR
        Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations.
        Am J Physiol. 1993; 265: F477-F486
        • Hutchison FN
        • Webster SK
        Effect of Ang II receptor antagonist on albuminuria and renal function in passive Heymann nephritis.
        Am J Physiol. 1992; 263: F311-F318
        • Tanaka R
        • Kon V
        • Yoshioka T
        • et al.
        Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms.
        Kidney Int. 1994; 45: 537-543
        • Krege JH
        • John SWM
        • Langenbach LL
        • et al.
        Male-female differences in fertility and blood pressure in ACE-deficient mice.
        Nature. 1995; 375: 146-148
        • Edelson JT
        • Weinstein MC
        • Tosteson ANA
        • et al.
        Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension.
        JAMA. 1990; 263: 407-413
        • McVeigh GE
        • Flack J
        • Grimm R
        Goals of antihypertensive therapy.
        Drugs. 1995; 49: 161-175

      Article info

      Identification

      DOI: https://doi.org/10.1016/0149-2918(95)80080-8

      Copyright

      © 1995 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX